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Introduction
•

•

•

•

Amiodarone, an antiarrhythmic and apixaban, an
anticoagulant have been associated with diffuse
alveolar hemorrhage (DAH).
Cases have been documented demonstrating DAH in
the setting of amiodarone and apixaban treatment,
however there are few cases examining DAH in
combination therapy.
We present a case of diffuse alveolar hemorrhage in the
setting of amiodarone and apixaban treatment for
paroxysmal atrial fibrillation.

Intervention
•

Amiodarone and Eliquis were discontinued

•

TB, autoimmune and viral panel and blood cultures were
negative

•

Despite extensive workup, she continued to have shortness of
breath, hemoptysis, and worsening cough.

•

She had minimal improvement on IV Furosemide and IV
Solumedrol

•

Bronchoscopy was performed and showed blood clots in the
upper airways and tracheo-bronchial tree. Diffuse alveolar
hemorrhage hemorrhagic bronchitis was noted primarily in the
right middle, and lower lobes and left lingula with no frank
purulence or abnormal secretions.

•

Case Presentation
•

•

•

A 69-year-old African American female with a
past medical history of heart failure with
preserved ejection fraction, hypertrophic
obstructive cardiomyopathy, neurofibromatosis
type 1 and permanent atrial fibrillation (On
Amiodarone and Apixaban) was admitted for
shortness of breath and hemoptysis.

•

DAH is a potentially life-threatening complication arising from the pulmonary
microcirculation and has variable presentations including but not limited to
hemoptysis, anemia, and hypoxic respiratory failure and diffuse lung
involvement.

•

Amiodarone is historically associated with alveolar and interstitial pneumonitis,
and reports of amiodarone induced DAH is limited.

•

In this case because the patient was taking amiodarone and apixaban, there is
the potential for drug-drug interaction that could have contributed to the severity
of the DAH.

•

For instance, amiodarone is a known CYP3A4 inactivator (Ohyama, 2001).
Apixaban has been shown to have increased levels in the blood when given with
strong inhibitors such as itraconazole.

•

Since apixaban is broken down via CYP34A, an inactivator such as amiodarone
could potentially cause an increase in the amount of circulating apixaban which
could increase the risk of DAH

•

Pulmonary complications are a rare occurrence in NF1 is also known to lead to
complications such as interstitial fibrosis and emphysema; which both can raise
the risk of DAH. (Ngygen 2018; Park 2013). However, there appear to be few
published studies that show correlation between NF1 and DAH.

After her bronchoscopy, the patient had improvement in her
shortness of breath, oxygenation and cough. She was aerating
on room air, and the hemoptysis resolved.
Given the patient’s coincident atrial fibrillation, it was felt that
the benefit of anticoagulation outweighed the risk of recurrent
bleeding, and the patient was continued on aspirin alone at
discharge.

chest x-ray showed new bilateral patchy
infiltrates worse on the right lower lobe, which
were not present on previous study from 2
weeks prior
On the first night of admission, the patient had
severe hemoptysis for which the patient
required two units of packed red blood cell
transfusion.

•

Repeat chest x-ray showed improved aeration in the right
lower lung field but mildly increased diffuse alveolar opacities.

•

NF1 is know to have higher risk for major bleeds due to
their friable vasculature.

Discussion

Conclusion
•

When considering anticoagulant therapy, clinicians should assess the
risks and benefits of starting the medical therapy, specifically bleeding
complications.

•

Apixaban related bleeding complications should be addressed
especially when the medication is administered concomitantly with
CYP3A4 inhibitors such as amiodarone. NF1 patient are knows to
have increased bleeding risk, anti-coagulation should be started under
careful supervision.

•

DAH is one of the potential bleeding complications of non-vitamin K
antagonist oral anticoagulants, which requires prompt intervention
including discontinuation of the offending medications, steroid
administration, and close respiratory monitoring.

•

Overall, careful monitoring and follow up should be a cornerstone
when implementing apixaban therapy.
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